Cervical cancer therapies: Current challenges and future perspectives

Burmeister, Carly A.; Khan, Saif F.; Schäfer, Georgia; Mbatani, Nomonde; Adams, Tracey; Moodley, Jennifer; Prince, Sharon

doi:10.1016/j.tvr.2022.200238

Cited by 179 publications

(104 citation statements)

References 159 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Different clinical trials have been conducted regarding immune checkpoint inhibitors (ICIs) and tumor-infiltrating lymphocytes (TILs) in cervical cancer [ 13 , 14 ]. ICIs act by releasing the so-called immune-suppressing brakes, including programmed death 1 (PD-1), its ligands programmed death ligand 1 (PD-L1) and programmed death ligand 2 (PD-L2), and cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) [ 15 ].…”

Section: Future Outlook On Cervical Cancer Therapymentioning

confidence: 99%

“…Lastly, promising results from adoptive T cell therapy (ACT) include cervical cancer. This approach involves collecting TILs from either the tumor tissue or blood of patients, expanding them ex vivo, and reinfusing them into the patient to effectively target cancer cells, particularly in the LN-145 TIL, an ACT in an ongoing phase-II trial [ 14 ]. Moreover, interleukin-2 (IL-2) seems to be a promising option for the treatment of patients with recurrent and/or metastatic cervical cancer.…”

Section: Future Outlook On Cervical Cancer Therapymentioning

confidence: 99%

“…Targeted therapy is the new accurate therapeutic strategy, using different means of inhibiting different proteins, which are specifically expressed by cancer cells and are responsible for controlling the growth, proliferation and spread of cancer, such as p53, tyrosine kinase Wee1, epidermal growth factor receptor (EGFR), vascular endothelial growth factor (VEGF) [ 13 , 14 ].…”

Section: Future Outlook On Cervical Cancer Therapymentioning

confidence: 99%

See 2 more Smart Citations

New Advances in Cervical Cancer: From Bench to Bedside

D’Oria

Corrado

Laganà

et al. 2022

IJERPH

View full text Add to dashboard Cite

Cervical cancer is the most common gynecologic malignancy and the fourth most common cancer in women worldwide. Over the last two decades, minimally invasive surgery (MIS) has emerged as the mainstay in the surgical management of early-stage cervical cancer, bringing advantages such as a lower operative morbidity and shorter hospital stay compared to open surgery, while maintaining comparable oncologic outcomes in numerous retrospective studies. Considering oncological patients, it is mandatory to assess the oncological outcomes and safety of this type of surgery. Moreover, there are different future outlooks on cervical cancer therapy, based on immunotherapy, target therapy, and poly-ADP-ribose polymerases (PARP) inhibitors in combination with each other, and in combination with standard chemotherapy and radiotherapy. The goal is to find an approach that is as personalized as possible.

show abstract

Section: Future Outlook On Cervical Cancer Therapymentioning

confidence: 99%

Section: Future Outlook On Cervical Cancer Therapymentioning

confidence: 99%

Section: Future Outlook On Cervical Cancer Therapymentioning

confidence: 99%

See 1 more Smart Citation

New Advances in Cervical Cancer: From Bench to Bedside

D’Oria

Corrado

Laganà

et al. 2022

IJERPH

View full text Add to dashboard Cite

show abstract

“…First-line treatment for patients with recurrent and/or metastatic CC includes the association of bevacizumab with chemotherapy. Important advances have been demonstrated in the last decade for second-line treatment with immunotherapy ( 71 – 73 ).…”

Section: Cervical Cancer Mitigation Through Vaccination Screening And...mentioning

confidence: 99%

Cervical cancer screening, treatment and prophylaxis in Brazil: Current and future perspectives for cervical cancer elimination

et al. 2022

View full text Add to dashboard Cite

As a middle-income country, Brazil has one of the largest public health systems worldwide, which deals with free and universal access to health care. Regarding cervical cancer, the country possesses a large infrastructure for the screening of premalignant and malignant lesions, but yet based on old technology, having Papanicolaou as the major screening method, followed by colposcopy and treatment. Also, large disparities in access are present, which makes effectiveness of screening and treatment in different regions of the country highly unequal. In this review, we describe and evaluate the current screening, treatment and prophylactic (HPV vaccination) strategies to combat cervical cancer in Brazil, and discuss potential incorporation of more recent technologies in these areas in the country to pave its way toward cervical cancer elimination.

show abstract

“…The clinical stage and pathological type of CC determine the treatment methods required by patients, including surgery, radiotherapy, and chemotherapy ( 6 ). For patients of CC with FIGO-stages IA-IB2, surgery is the main modality for treatment.…”

Section: Introductionmentioning

confidence: 99%

Nimotuzumab combined with chemoradiotherapy for the treatment of cervical cancer: A meta-analysis of randomized controlled trials

et al. 2022

View full text Add to dashboard Cite

ObjectivesTo assess the clinical efficacy and toxicity of nimotuzumab in combination with chemoradiotherapy or chemoradiotherapy alone in the treatment of cervical cancer.MethodsThe PubMed, Embase, Cochrane Library, Web of Science, China National Knowledge Infrastructure, China Biomedical Medicine, Wanfang, and VIP databases were systematically searched for relevant literature. Ultimately, six randomised controlled trials (n=393) were included in our meta-analysis.ResultsA total of 393 patients were included, of which 197 were in the nimotuzumab combined with chemoradiotherapy group and 196 were in the chemoradiotherapy group. The results of our meta-analysis showed that the complete remission rate (risk ratio [RR] = 1.34, 95% confidence interval [CI]: 1.08-1.65, P = 0.007), objective response rate (RR = 1.30, 95% CI: 1.16-1.44, P < 0.05), and three-year survival rate (RR = 1.27, 95% CI: 1.06-1.51, P = 0.008) in the nimotuzumab combined with chemoradiotherapy group were significantly improved compared with the chemoradiotherapy group. This difference was not statistically significant when comparing the incidence of adverse reactions (such as leukocytopenia, gastrointestinal reaction, radiocystitis, and radioproctitis) between the two groups.ConclusionsNimotuzumab in combination with chemoradiotherapy has some advantages over chemoradiotherapy alone in the treatment of cervical cancer and does not increase toxicity. Therefore, nimotuzumab has the potential to be an effective treatment for cervical cancer; however, further evidence from large-scale randomised controlled trials is needed.

show abstract

Cervical cancer therapies: Current challenges and future perspectives

Cited by 179 publications

References 159 publications

New Advances in Cervical Cancer: From Bench to Bedside

New Advances in Cervical Cancer: From Bench to Bedside

Cervical cancer screening, treatment and prophylaxis in Brazil: Current and future perspectives for cervical cancer elimination

Nimotuzumab combined with chemoradiotherapy for the treatment of cervical cancer: A meta-analysis of randomized controlled trials

Contact Info

Product

Resources

About